BCMA Targeted Therapies Summit
Revolutionize your BCMA pipeline
Rhianna Price
adc, BCMA, CAR T, multiple myeloma, Oncology
0 Comment
Revolutionize your BCMA pipeline
Ellie Saunders
cancer, CAR T, cell therapy, Oncology, T-cell
0 Comment
Engineering Smarter Adoptive Cell Therapies
Phil Taylor
Allogene, CAR T, cell therapy, immuno-oncology, lymphoma, Oncology, safety
0 Comment
Richard Staines
Allogene, CAR T, Gilead, Kite Pharma, non-Hodgkin lymphoma, Oncology
0 Comment
R&D/ Views & Analysis/ Views and analysis
mike.hammerton@pharmaphorum.com
CAR T, cell therapy, Gilead, Kite
0 Comment
Richard Staines
Abecma, Bristol-Myers Squibb, CAR T, multiple myeloma
0 Comment
Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis
Susan Wormald
CAR T, cell therapy, Gilead, Kite, lymphoma, Lymphoma Action, patients
0 Comment
Richard Staines
CAR T, Gilead, Kite, lymphoma, market access, NICE, Oncology, Tecartus
0 Comment
Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis
mike.hammerton@pharmaphorum.com
cancer, CAR T, cell therapy, EU, Europe, Gilead, Kite, manufacturing
0 Comment